Novartis AG Ownership of Tourmaline Bio, Inc. Common Stock

Novartis AG, through its indirect wholly-owned subsidiary Torino Merger Sub Inc., owns 24,030,382 shares of common stock in Tourmaline Bio, Inc. The ownership is reported as indirect, and the shares are held at a par value of $0.0001. The filing, submitted under Form 3, indicates that Novartis AG is a ten percent owner of Tourmaline Bio, Inc. The period of report is October 28, 2025, and the document was signed by attorneys Jonathan Emery and Ram Narayan on behalf of Novartis AG.